Media Release

Straumann Emdogain® launched in new wound-healing indication

- Benefits of enhanced wound healing include reduced risk of complications and pain after surgery, improved esthetic outcomes and greater patient satisfaction.
- Straumann is the first company in the field of tooth replacement to launch a biologic material to enhance wound healing as part of dental implant procedures in general.
- Indication supported by strong scientific evidence and results from experienced user surveys
- New indication cleared in Europe with regulatory approvals pending in other regions.

Basel, 3 May 2016: Straumann today announced the launch of its oral-tissue regeneration product Emdogain® in the new indication of soft-tissue wound healing as part of oral surgical procedures and dental implantation procedures in general.

The benefits of enhanced wound healing include reduced risk of post-surgical complications, reduced post-surgical pain, swelling and discomfort, improved esthetic outcomes and greater patient satisfaction. Straumann is the first company in the field of tooth replacement to launch a biologic material to enhance wound healing as part of dental implant procedures in general. The company is launching Emdogain in the new indication in Europe with other regional markets to follow pending regulatory clearances.

Straumann Emdogain is one of the most established and widely-studied dental treatments and, having been used to treat more than 2 million patients over the past 20 years, it has become the gold standard for periodontal regeneration.

Since its discovery, researchers have acknowledged that the proteins in enamel matrix derivatives (EMD), the product's active principle, have a broad biologic function including the stimulation and modulation of healing in general. 150 scientific publications and reviews have described the effect on wound healing. Research has led to the establishment of EMD in treating hard-to-heal wounds like diabetic foot ulcers with excellent clinical results. Recent scientific publications[1],[2],[3] demonstrate the potential of Straumann Emdogain to induce faster re-epithelialization, faster wound closure, faster resolution of inflammation and faster extended blood-vessel formation.

Excellent clinical outcomes regarding the quality of oral soft-tissue wound healing have been reported in an international survey with 112 participants in the US, Germany and Italy. The results were remarkably consistent, showing that approximately 85% of Emdogain users confirmed that it improves soft-tissue wound healing.

While the potential of Emdogain to stimulate wound healing is clearly documented, Straumann is committed to working with clinical experts to establish its use in key indications, for example to support/enhance treatment with Straumann's new Bone Level Tapered Implant or Pro Arch solution in esthetic and immediate replacement procedures.

About Straumann
Headquartered in Basel, Switzerland, Straumann (SIX: STMN) is a global leader in implant, restorative and regenerative dentistry. In collaboration with leading clinics, research institutes and universities, Straumann researches, develops and manufactures dental implants, instruments, prosthetics and biomaterials for use in tooth replacement and restoration solutions or to prevent tooth loss. Straumann currently employs approximately 3500 people worldwide and its products and services are available in more than 100 countries through its broad network of distribution subsidiaries and partners.

Straumann Holding AG, Peter Merian-Weg 12, 4002 Basel, Switzerland.
Phone: +41 (0)61 965 11 11 / Fax: +41 (0)61 965 11 01
E-mail: investor.relations@straumann.com / corporate.communication@straumann.com
Homepage: www.straumann.com

CONTACTS

Corporate Communication:
Mark Hill, +41 (0)61 965 13 21
Thomas Konrad, +41 (0)61 965 15 46

Investor Relations:
Fabian Hildbrand, +41 (0)61 965 13 27

Disclaimer
This release contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this release. Straumann is providing the information in this release as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.

Straumann Media Releases subscription:
http://www.straumann.com/en/home/media/media-releases.news.rss

Straumann Social Media Channels
http://www.straumann.com/en/home/about-straumann/social-media.html

RSS feed subscription:
http://www.straumann.com/en/home/media/media-releases.news.rss

Straumann Media Center
smc.straumann.com (Login: “Corporate”; Password: “corporate”)

---

[1] A Proline-Rich Peptide Mimic Effects of EMD in Rat Oral Mucosal Incisional Wound Healing. Villa O, Wohlfahrt JC, Mdla I, Petzold C, Reseland JE, Snead ML, Lyngstadaas SP. J Periodontol. 2015 Dec;86(12):1386-95.
[2] Some effects of enamel matrix proteins on wound healing in the dento-gingival region. Wennström JL, Lindhe J. J Clin Periodontol. 2002 Jan;29(1):9-14.
[3] Microvessel Density Evaluation of the Effect of Enamel Matrix Derivative on Soft Tissue After Implant Placement: A Preliminary Study. Guimarães GF, de Araújo VC, Nery JC, Peruzzo DC, Soares AB. Int J Periodontics Restorative Dent. 2015 Sep-Oct;35(5):733-8.

# # #